VU10010

CAS No. 633283-39-3

VU10010( VU 10010 )

Catalog No. M27734 CAS No. 633283-39-3

VU 10010 is allosteric potentiator of M4 acetylcholine receptors.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 43 In Stock
5MG 72 In Stock
10MG 115 In Stock
25MG 237 In Stock
50MG 375 In Stock
100MG 552 In Stock
500MG 1161 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    VU10010
  • Note
    Research use only, not for human use.
  • Brief Description
    VU 10010 is allosteric potentiator of M4 acetylcholine receptors.
  • Description
    VU 10010 is allosteric potentiator of M4 acetylcholine receptors.
  • In Vitro
    VU10010 potentiates the M4 response to acetylcholine 47-fold while having no activity at other mAChR subtypes (rM1, rM2, rM3 or rM5). VU10010 causes an increase in affinity for ACh and M4-mediated [35S]GTPγS binding. VU10010 (10 μM) has no agonist, antagonist or allosteric potentiator activity at P2Y1R or mGluR5. The EC50 values are 33 and 0.7 nM for ACh in the absence and presence of VU10010, respectively.
  • In Vivo
    ——
  • Synonyms
    VU 10010
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    AChR
  • Recptor
    hCB1
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    633283-39-3
  • Formula Weight
    345.85
  • Molecular Formula
    C17H16ClN3OS
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (361.43 mM)
  • SMILES
    Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Wang X, et al. Effects of the allosteric antagonist 1-(4-chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl]urea (PSNCBAM-1) on CB1 receptor modulation in the cerebellum. Mol Pharmacol. 2011 Apr;79(4):758-67.
molnova catalog
related products
  • Metixene hydrochlori...

    Metixene hydrochloride hydrate has potential anticholinergic activity and inhibits the binding of quinine ring benzoate (QNB) to muscarine receptors, with IC50 and Ki values of 55 nM and 15 nM, respectively.

  • GAT107

    GAT107 is a novel and potent α7 nicotinic cholinergic receptor modifier agonist and modulator with anti-inflammatory activity that reverses injury perception in a mouse model of neuropathic pain.

  • SSR180711 hydrochlor...

    SSR180711 hydrochloride (SSR-180711A HCl) is a selective Alpha7 nicotinic acetylcholine partial agonist for the study of neurodegenerative and cognitive disorders.